Acuson reports stable first quarter
Ultrasound vendor Acuson of Mountain View, CA, reported single-digit growth in sales for its first quarter (end-April), while net income dipped slightly. The company reported that U.S. sales remain stable, while international shipments increased 4%
Ultrasound vendor Acuson of Mountain View, CA, reported single-digit growth in sales for its first quarter (end-April), while net income dipped slightly. The company reported that U.S. sales remain stable, while international shipments increased 4% thanks to the shipment of a large order to China.
For the period, Acuson logged $119 million in sales, up 2.8% compared with $115.8 million in revenues in the first quarter of 1998. The company posted net income of $5.5 million in the quarter, compared with net income of $5.7 million in the corresponding quarter a year ago. Acusons operating income was higher this quarter than a year ago, but the companys net profit was reduced by a $1 million charge for interest expense.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
